These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34649258)

  • 1. Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study.
    Abdel-Rahman O; Koski SL
    Neuroendocrinology; 2022; 112(8):777-783. PubMed ID: 34649258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
    Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
    Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
    Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
    JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
    Sama S; Kerrigan K; Sinnott JA; Puri S; Akerley W; Haaland B; Patel S
    Cancer Treat Res Commun; 2023; 35():100686. PubMed ID: 36736060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
    Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
    J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
    Hatfield LA; Huskamp HA; Lamont EB
    J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
    Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
    J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
    Ueki H; Terakawa T; Hara T; Hirata J; Jimbo N; Okamura Y; Bando Y; Furukawa J; Harada K; Nakano Y; Fujisawa M
    Jpn J Clin Oncol; 2023 Jun; 53(6):522-529. PubMed ID: 36828781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
    Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Iwasaki T; Takenaga N; Kasahara Y; Ouchi K; Shirota H; Takahashi M; Ishioka C
    Oncology; 2024; 102(5):359-367. PubMed ID: 37903486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
    Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
    Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS
    JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.
    Guan Y; Yao Q; Hao Y; Zeng X; Wang W; Gu X; Xiang J; Sun Y; Song Z
    Cancer Med; 2023 Aug; 12(15):16011-16018. PubMed ID: 37351565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.
    Stefàno E; De Castro F; Ciccarese A; Muscella A; Marsigliante S; Benedetti M; Fanizzi FP
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix.
    Miyoshi AI; Ueda Y; Kurita T; Kimura T; Yoshino K
    Anticancer Res; 2023 Apr; 43(4):1397-1405. PubMed ID: 36974776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
    Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
    Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
    Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study.
    Salvo G; Flores Legarreta A; Ramalingam P; Jhingran A; Bhosale P; Saab R; Gonzales NR; Chisholm GB; Frumovitz M
    Int J Gynecol Cancer; 2023 Sep; 33(9):1359-1369. PubMed ID: 37567596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.